{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:46:12Z","timestamp":1792500372458,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejmech.2023.116058","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T07:49:06Z","timestamp":1702885746000},"page":"116058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The significance of persisters in tuberculosis drug discovery: Exploring the potential of targeting the glyoxylate shunt pathway"],"prefix":"10.1016","volume":"265","author":[{"given":"Anjali","family":"Negi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0686-7126","authenticated-orcid":false,"given":"Rashmi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.116058_bib1","unstructured":"Global TB Report 2023.Pdf, (n.d.)."},{"key":"10.1016\/j.ejmech.2023.116058_bib2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a017830","article-title":"Diagnosis and management of latent tuberculosis infection: table 1","volume":"5","author":"Mu\u00f1oz","year":"2015","journal-title":"Cold Spring Harb. Perspect Med."},{"key":"10.1016\/j.ejmech.2023.116058_bib3","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3390\/microorganisms11092277","article-title":"Tackling drug-resistant tuberculosis: new challenges from the old pathogen Mycobacterium tuberculosis","volume":"11","author":"Mancuso","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2023.116058_bib4","first-page":"62","volume":"vol. 43","author":"Kiazyk","year":"2017"},{"key":"10.1016\/j.ejmech.2023.116058_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2023.116058_bib6","article-title":"Targeting non-replicating Mycobacterium tuberculosis and latent infection: alternatives and perspectives (Mini-Review)","volume":"22","author":"Egorova","year":"2021","journal-title":"Int. J. Math. Stat."},{"issue":"2020","key":"10.1016\/j.ejmech.2023.116058_bib7","article-title":"Diagnosis for latent tuberculosis infection: new alternatives","volume":"11","author":"Carranza","year":"2006","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.116058_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/metabo11020088","article-title":"Metabolic versatility of Mycobacterium tuberculosis during infection and dormancy","volume":"11","author":"Chang","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.ejmech.2023.116058_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4046\/trd.2017.0052","article-title":"Treatment of latent tuberculosis infection and its clinical efficacy","volume":"81","author":"Kim","year":"2018","journal-title":"Tuberc. Respir. Dis."},{"key":"10.1016\/j.ejmech.2023.116058_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/IDR.S8994","article-title":"The use of anti-tuberculosis therapy for latent TB infection","author":"Denholm","year":"2010","journal-title":"IDR"},{"key":"10.1016\/j.ejmech.2023.116058_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114906","article-title":"Screening approaches and therapeutic targets: the two driving wheels of tuberculosis drug discovery","volume":"197","author":"Perveen","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116058_bib12","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1016\/j.bmcl.2011.07.062","article-title":"Synthesis of various 3-nitropropionamides as Mycobacterium tuberculosis isocitrate lyase inhibitor","volume":"21","author":"Sriram","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.116058_bib13","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/biomedicines10102398","article-title":"Latent tuberculosis: a promising new compound to treat non-replicating and intramacrophagic mycobacteria","volume":"10","author":"Campos","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2023.116058_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001065","article-title":"Metabolic regulation of mycobacterial growth and antibiotic sensitivity","volume":"9","author":"Baek","year":"2011","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2023.116058_bib15","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1021\/acs.jmedchem.6b00674","article-title":"Inhibitors of the cysteine synthase CysM with antibacterial potency against dormant Mycobacterium tuberculosis","volume":"59","author":"Brunner","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116058_bib16","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1074\/jbc.M209248200","article-title":"Biochemical and structural studies of malate synthase fromMycobacterium tuberculosis","volume":"278","author":"Smith","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.116058_bib17","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1080\/07391102.2020.1758787","article-title":"Structure-based discovery of phenyl-diketo acids derivatives as Mycobacterium tuberculosis malate synthase inhibitors","volume":"39","author":"Shukla","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2023.116058_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12026-011-8229-7","article-title":"Latent tuberculosis: what the host \u201csees\u201d","volume":"50","author":"Gideon","year":"2011","journal-title":"Immunol. Res."},{"key":"10.1016\/j.ejmech.2023.116058_bib19","unstructured":"Global TB Report 2022.Pdf, (n.d.)."},{"key":"10.1016\/j.ejmech.2023.116058_bib20","first-page":"1","article-title":"Updates on the risk factors for latent tuberculosis reactivation and their managements","volume":"5","author":"Ai","year":"2016","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.ejmech.2023.116058_bib21","unstructured":"Zak et al 2016.pdf, (n.d.)."},{"key":"10.1016\/j.ejmech.2023.116058_bib22","first-page":"48","article-title":"The biological and clinical aspects of a latent tuberculosis infection","volume":"7","author":"Khabibullina","year":"2022","journal-title":"Trop. Med."},{"key":"10.1016\/j.ejmech.2023.116058_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.593497","article-title":"A multi-pronged computational pipeline for prioritizing drug target strategies for latent tuberculosis","volume":"8","author":"Banerjee","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2023.116058_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00159-19","article-title":"Caseum: a niche for Mycobacterium tuberculosis drug-tolerant persisters","volume":"33","author":"Sarathy","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2023.116058_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1079569","article-title":"Tuberculosis: the success tale of less explored dormant Mycobacterium tuberculosis","volume":"12","author":"Verma","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib26","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2741\/1291","article-title":"Persistent and dormant tubercle bacilli and latent tuberculosis","volume":"9","author":"Zhang","year":"2004","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2023.116058_bib27","article-title":"Metabolic flux partitioning between the TCA cycle and glyoxylate shunt combined with a reversible methyl citrate cycle provide nutritional flexibility for Mycobacterium tuberculosis","author":"Borah","year":"2021","journal-title":"Syst. Biol."},{"key":"10.1016\/j.ejmech.2023.116058_bib28","unstructured":"C.G. Quinonez, NOVEL INHIBITORS FOR ISOCITRATE LYASE AS A POTENT ANTITUBERCULAR AGENT FOR MYCOBACTERIUM TUBERCULOSIS, (n.d.). ."},{"key":"10.1016\/j.ejmech.2023.116058_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.mib.2022.102191","article-title":"Bottlenecks and opportunities in antibiotic discovery against Mycobacterium tuberculosis","volume":"69","author":"Craggs","year":"2022","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00695-22","article-title":"Combination therapy to kill Mycobacterium tuberculosis in its nonreplicating persister phenotype","volume":"66","author":"Yamada","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.116058_bib31","unstructured":"N. Hange, M.R. Somagutta, A. Sharma, K. Agadi, N.N. Ngaba, N. Paikkattil, Latent Tuberculosis: Challenges and Opportunities for Diagnosis and Treatment, (n.d.). ."},{"key":"10.1016\/j.ejmech.2023.116058_bib32","series-title":"Latent Tuberculosis in India: an Overview","author":"Vishwakarma","year":"2023"},{"key":"10.1016\/j.ejmech.2023.116058_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02948-22","article-title":"Noise in a metabolic pathway leads to persister formation in Mycobacterium tuberculosis","volume":"10","author":"Quigley","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejmech.2023.116058_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41579-019-0196-3","article-title":"Definitions and guidelines for research on antibiotic persistence","volume":"17","author":"Balaban","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib35","article-title":"Persistence of Mycobacterium tuberculosis in response to infection burden and host-induced stressors","volume":"12","author":"Parbhoo","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1099\/mic.0.000760","article-title":"The relevance of persisters in tuberculosis drug discovery","volume":"165","author":"Mandal","year":"2019","journal-title":"Microbiology"},{"key":"10.1016\/j.ejmech.2023.116058_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155127","article-title":"High persister mutants in Mycobacterium tuberculosis","volume":"11","author":"Torrey","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.116058_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2014.80","article-title":"Persisters, persistent infections and the Yin\u2013Yang model","volume":"3","author":"Zhang","year":"2014","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.ejmech.2023.116058_bib39","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1128\/AAC.02202-12","article-title":"Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis","volume":"57","author":"Sarathy","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.116058_bib40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.tube.2016.05.006","article-title":"Defining dormancy in mycobacterial disease","volume":"99","author":"Lipworth","year":"2016","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2023.116058_bib41","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nrmicro955","article-title":"Persistent bacterial infections: the interface of the pathogen and the host immune system","volume":"2","author":"Monack","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib42","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.drudis.2017.04.012","article-title":"Targeting isocitrate lyase for the treatment of latent tuberculosis","volume":"22","author":"Bhusal","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.116058_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.tube.2017.07.006","article-title":"Down-regulation of malate synthase in Mycobacterium tuberculosis H37Ra leads to reduced stress tolerance, persistence and survival in macrophages","volume":"106","author":"Singh","year":"2017","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2023.116058_bib44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.chembiol.2009.12.014","article-title":"Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets","volume":"17","author":"Olaleye","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116058_bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/cbdd.12655","article-title":"Design and development of Mycobacterium tuberculosis lysine \u025b \u2010aminotransferase inhibitors for latent tuberculosis infection","volume":"87","author":"Parthiban","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2023.116058_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155522","article-title":"Role of alanine dehydrogenase of Mycobacterium tuberculosis during recovery from hypoxic nonreplicating persistence","volume":"11","author":"Giffin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.116058_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02526-22","article-title":"Mycobacterium tuberculosis Rv1324 protein contributes to mycobacterial persistence and causes pathological lung injury in mice by inducing ferroptosis","volume":"11","author":"Shi","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejmech.2023.116058_bib48","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001695","article-title":"Unravelling the flexibility of Mycobacterium tuberculosis: an escape way for the bacilli","volume":"72","author":"Sau","year":"2023","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/17460441.2023.2157811","article-title":"Advances in the design of combination therapies for the treatment of tuberculosis","volume":"18","author":"Larkins-Ford","year":"2023","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.116058_bib50","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.ijmyco.2016.09.061","article-title":"Activity of drugs against dormant Mycobacterium tuberculosis","volume":"5","author":"Iacobino","year":"2016","journal-title":"Int. J. Mycobacteriol."},{"key":"10.1016\/j.ejmech.2023.116058_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01586-16","article-title":"Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application","volume":"8","author":"Kerantzas","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2023.116058_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.958555","article-title":"Understanding the contribution of metabolism to Mycobacterium tuberculosis drug tolerance","volume":"12","author":"Samuels","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib53","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/mmi.14362","article-title":"Mycobacterium tuberculosis requires glyoxylate shunt and reverse methylcitrate cycle for lactate and pyruvate metabolism","volume":"112","author":"Serafini","year":"2019","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib54","series-title":"Reconciling the Spectrum of Sagittarius A* with a Two-Temperature Plasma Model","first-page":"396","author":"Mahadevan","year":"1998"},{"key":"10.1016\/j.ejmech.2023.116058_bib55","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nm1252","article-title":"Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence","volume":"11","author":"Mu\u00f1oz-El\u00edas","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.116058_bib56","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211215","article-title":"Mycobacterium tuberculosis carbon and nitrogen metabolic fluxes","author":"Xu","year":"2022","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejmech.2023.116058_bib57","first-page":"1","article-title":"Potential inhibitors for isocitrate lyase of Mycobacterium tuberculosis and non- M. tuberculosis : a summary","author":"Lee","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2023.116058_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/77964","article-title":"Structure of isocitrate lyase, a a persistence factor of","volume":"7","author":"Sharma","year":"2000","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ejmech.2023.116058_bib59","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1099\/mic.0.030858-0","article-title":"Major roles of isocitrate lyase and malate synthase in bacterial and fungal pathogenesis","volume":"155","author":"Dunn","year":"2009","journal-title":"Microbiology"},{"key":"10.1016\/j.ejmech.2023.116058_bib60","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nm1252","article-title":"Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence","volume":"11","author":"Mu\u00f1oz-El\u00edas","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.116058_bib61","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1365-2958.2006.05297.x","article-title":"Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis","volume":"61","author":"Gould","year":"2006","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib62","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1365-2958.2006.05151.x","article-title":"Mycobacterium tuberculosis malate synthase is a laminin-binding adhesin","volume":"60","author":"Kinhikar","year":"2006","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib63","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1617655114","article-title":"Glyoxylate detoxification is an essential function of malate synthase required for carbon assimilation in Mycobacterium tuberculosis","volume":"114","author":"Puckett","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.116058_bib64","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ddr.20152","article-title":"A high throughput screening approach to identify isocitrate lyase inhibitors from traditional Chinese medicine sources","volume":"67","author":"Bai","year":"2006","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2023.116058_bib65","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000299795","article-title":"In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis","volume":"85","author":"Lu","year":"2010","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejmech.2023.116058_bib66","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00284-010-9837-5","article-title":"Microarray analysis of the chelerythrine-induced transcriptome of Mycobacterium tuberculosis","volume":"62","author":"Liang","year":"2011","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116058_bib67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejmech.2010.10.020","article-title":"Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection","volume":"46","author":"Banerjee","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116058_bib68","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1016\/j.bmcl.2010.06.096","article-title":"5-Nitro-2-furoic acid hydrazones: design, synthesis and in vitro antimycobacterial evaluation against log and starved phase cultures","volume":"20","author":"Sriram","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.116058_bib69","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/14756360903425221","article-title":"5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies","volume":"25","author":"Sriram","year":"2010","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116058_bib70","article-title":"Novel pthalazinyl derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis isocitrate lyase enzyme","volume":"5","author":"Sriram","year":"2009","journal-title":"MC"},{"key":"10.1016\/j.ejmech.2023.116058_bib71","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1016\/j.bmc.2014.05.064","article-title":"Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates","volume":"22","author":"Kr\u00e1tk\u00fd","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116058_bib72","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.tube.2012.06.001","article-title":"Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase","volume":"92","author":"Kr\u00e1tk\u00fd","year":"2012","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2023.116058_bib73","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/oli.2005.15.215","article-title":"DNAzymes targeting the icl gene inhibit ICL expression and decrease Mycobacterium tuberculosis survival in macrophages","volume":"15","author":"Li","year":"2005","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.ejmech.2023.116058_bib74","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7150\/ijbs.7.376","article-title":"Identification of Mannich base as a novel inhibitor of Mycobacterium tuberculosis isocitrate by high-throughput screening","volume":"7","author":"Ji","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2023.116058_bib75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.tube.2015.12.003","article-title":"Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating","volume":"97","author":"Liu","year":"2016","journal-title":"Mycobact. Tubercul.Tubercul."},{"key":"10.1016\/j.ejmech.2023.116058_bib76","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1016\/j.bmcl.2012.03.047","article-title":"Synthesis and characterization of pyruvate\u2013isoniazid analogs and their copper complexes as potential ICL inhibitors","volume":"22","author":"Shingnapurkar","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.116058_bib77","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.tube.2009.05.008","article-title":"High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv","volume":"89","author":"Ananthan","year":"2009","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2023.116058_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106252","article-title":"Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase","volume":"176","author":"Kr\u00e1tk\u00fd","year":"2022","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2023.116058_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2021.103581","article-title":"Antitubercular and antioxidant activities of hydroxy and chloro substituted chalcone analogues: synthesis, biological and computational studies","volume":"15","author":"Ammaji","year":"2022","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.ejmech.2023.116058_bib80","doi-asserted-by":"crossref","first-page":"17666","DOI":"10.1021\/jacs.1c07970","article-title":"Mechanism-based inactivation of Mycobacterium tuberculosis isocitrate lyase 1 by (2 R ,3 S)-2-Hydroxy-3-(nitromethyl)succinic acid","volume":"143","author":"Mellott","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.116058_bib81","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1021\/acschembio.0c00740","article-title":"Covalent inactivation of Mycobacterium tuberculosis isocitrate lyase by cis -2,3-Epoxy-Succinic acid","volume":"16","author":"Pham","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116058_bib82","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.chembiol.2012.09.018","article-title":"Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase","volume":"19","author":"Krieger","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116058_bib83","unstructured":"R. Kumar, Glyoxylate Shunt: Combating Mycobacterium at Forefront, (n.d.). ."},{"key":"10.1016\/j.ejmech.2023.116058_bib84","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/jcb.27538","article-title":"Structural and energetic understanding of novel natural inhibitors of Mycobacterium tuberculosis malate synthase","volume":"120","author":"Shukla","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2023.116058_bib85","doi-asserted-by":"crossref","first-page":"27421","DOI":"10.1074\/jbc.M116.750877","article-title":"Mycobacterium tuberculosis malate synthase structures with fragments reveal a portal for substrate\/product exchange","volume":"291","author":"Huang","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.116058_bib86","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1128\/jb.131.1.136-144.1977","article-title":"Itaconate, an isocitrate lyase-directed inhibitor in Pseudomonas indigofera","volume":"131","author":"McFadden","year":"1977","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejmech.2023.116058_bib87","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1021\/bi00261a035","article-title":"Inhibition of isocitrate lyase by 3-nitropropionate, a reaction-intermediate analog","volume":"21","author":"Schloss","year":"1982","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.116058_bib88","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1016\/j.bmcl.2012.03.047","article-title":"Synthesis and characterization of pyruvate\u2013isoniazid analogs and their copper complexes as potential ICL inhibitors","volume":"22","author":"Shingnapurkar","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.116058_bib89","unstructured":"Duan et al 2022.pdf, (n.d.)."},{"key":"10.1016\/j.ejmech.2023.116058_bib90","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1016\/j.bmc.2014.05.064","article-title":"Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates","volume":"22","author":"Kr\u00e1tk\u00fd","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116058_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251067","article-title":"Heterogeneous multimeric structure of isocitrate lyase in complex with succinate and itaconate provides novel insights into its inhibitory mechanism","volume":"16","author":"Kwon","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.116058_bib92","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1021\/acschembio.8b00225","article-title":"The nitro group as a masked electrophile in covalent enzyme inhibition","volume":"13","author":"Ray","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116058_bib93","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Zhang","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2023.116058_bib94","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MGM2-0023-2013","article-title":"Mechanisms of pyrazinamide action and resistance","volume":"2","author":"Zhang","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejmech.2023.116058_bib95","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.06288-11","article-title":"Targeting persisters for tuberculosis control","volume":"56","author":"Zhang","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.116058_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2021.100115","article-title":"Probes and techniques used in active and the hypoxia-based dormant state of an antitubercular drug screening assay","volume":"13","author":"Yeware","year":"2022","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.116058_bib97","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallis","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2023.116058_bib98","unstructured":"Maiga et al 2012.pdf, (n.d.)."},{"key":"10.1016\/j.ejmech.2023.116058_bib99","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3390\/app10072278","article-title":"Mycobacterial cell wall: a source of successful targets for old and new drugs","volume":"10","author":"Vilch\u00e8ze","year":"2020","journal-title":"Appl. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423010255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423010255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T14:47:51Z","timestamp":1736866071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423010255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":99,"alternative-id":["S0223523423010255"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116058","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The significance of persisters in tuberculosis drug discovery: Exploring the potential of targeting the glyoxylate shunt pathway","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116058"}}